<DOC>
	<DOCNO>NCT00004420</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine efficacy safety gammalinolenic acid treatment childhood arthritis .</brief_summary>
	<brief_title>Study Gammalinolenic Acid Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control , cross study 12 month duration . Patients stratify type juvenile rheumatoid arthritis ( systemic onset v pauciarticular disease v polyarticular disease ) . Patients randomize receive either gammalinolenic acid ( GLA ) placebo ( safflower seed oil ) orally . Parents ask maintain child 's usual diet course study . Patients follow 3 , 6 , 9 , 12 month study 6 month thereafter .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Efamol</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Juvenile rheumatoid arthritis ( systemic onset , pauciarticular disease , polyarticular disease ) Active synovitis Prior/Concurrent Therapy No 2 concurrent nonsteroidal antiinflammatory drug No 2 concurrent second line agent ( e.g. , Dpenicillamine , oral injectable gold , antimalarial , methotrexate , sulfasalazine ) Must start second line agent least 3 month prior study Must stable dos medication least 1 month prior study Prior prednisone allow start least 3 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>juvenile rheumatoid arthritis</keyword>
	<keyword>rare disease</keyword>
</DOC>